Intended Audience
This complimentary CME educational activity is designed for all oncologists, surgical oncologists, radiologists, oncology nurses, and other health care professionals managing patients with metastatic breast cancer.
Program Medium
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period January 25, 2013 through January 25, 2015 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 101 segments totaling 3.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate
Estimated Time to Complete Educational Activity
3.5 hours
Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances the management of metastatic breast cancer.
Release Date
January 25, 2013
Expiration Date
January 25, 2015
Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Metastatic Breast Cancer is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
Supported by an educational grant from Eisai, Inc.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Complete Conference Management and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Complete Conference Management designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of Complete Conference Management to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by Complete Conference Management are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Ricardo Alvarez, MD, MSc
Assistant Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Assistant Professor, The Morgan Welch Inflammatory
Breast Cancer Research Program and Clinic
Houston, Texas
Nothing to disclose
Stefan Gl?ck, MD, PhD
Professor of Medicine
Miller School of Medicine
University of Miami
Clinical Director, Braman Family Breast Cancer Institute
Sylvester Comprehensive Cancer Center
Research Support: Amgen, Agendia, Celgene, GSK, GHI, Eisai
Consultant/Advisory Board: Amgen, Agendia, Celgene, GSK, GHI, Eisai
William J. Gradishar, MD
Professor of Medicine
Division of Hematology and Medical Oncology
Feinberg School of Medicine at Northwestern University
Director of Breast Medical Oncology
Associate Director, Lynn Sage Comprehensive Breast Program
Chicago, Illinois
Research Support: Eisai
Peter A. Kaufman, MD
Associate Professor of Medicine
Department of Medical Oncology and Hematology
Dartmouth Medical School
Norris Cotton Cancer Center
Lebanon, New Hampshire
Research Support: Genentech
Consultant: Genentech
Virginia Kaklamani, MD
Associate Professor
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Research Support: Eisai
Speaker Honoraria: Celgene, Genentech
Advisory Board: Celgene, Genentech
Minetta Liu, MD
Assistant Professor, Division of Hematology/Oncology
Department of Medicine
Lombardi Comprehensive Cancer Center
Mayo Clinic
Rochester, MD
Research Support: Eisai
Susan L. Mooberry, PhD
Professor of Pharmacology
Co-leader of Experimental and Developmental Therapeutics
Cancer Therapy and Research Center
University of Texas Health Science Center at San Antonio
University of Texas
San Antonio, Texas
Research Grant: Remeditex Ventures
Advisory Board: Eisai
Joyce O'Shaughnessy, MD
Baylor-Sammons Cancer Center in Dallas
Co-Chair, Breast Cancer Research
Chair, Cancer Prevention Research
U.S. Oncology Clinical Trials Network
Houston, Texas
Honorarium: Abraxis BioScience, AstraZeneca, Genentech BioOncology, GlaxoSmithKline, sanofi-aventis Group
Edith Perez, MD
Professor of Medicine
Mayo Medical School
Director of the Breast Program
Chair of the Cancer Clinical Study Unit
Mayo Clinic, Florida
Grant/Research Support: Sanofi Oncology, Genentech, GSK
Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Speaker's Bureau: Genomic Health
Grant/Research Support: Abbott, BMS, GSK, Genentech, Novartis, Merck, Sanofi- Aventis
Lee S. Schwartzberg, MD FACP
Medical Director, The West Clinic
Clinical Professor of Medicine
University of Tennessee College of Medicine
Memphis, Tennessee
Grant/Research Support: Eisai, BMS
Speaker Honoraria: Eisai
Katherine H. Rak Tkaczuk, MD
Professor of Medicine and Oncology
Director, Breast Evaluation and Treatment Program
Medical Oncologist?
University of Maryland Medical Center
Baltimore, Maryland
Nothing to disclose
Tiffany A. Traina, MD
Assistant Professor
Weill Medical College of Cornell University
Assistant Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Research Support: Eisai
Speaker/Honoraria: Eisai
Advisory Board: Genentech
Debu Tripathy, MD
Professor of Medicine
Priscilla and Art Ulene Chair in Women’s Cancer
Co-Leader, Women's Cancer Program
University of Southern California
Los Angeles, California
Nothing to disclose
Professor Christopher Twelves, MD
NTRAC Professor of Clinical Cancer Pharmacology and Oncology
Professor and Honorary Consultant in Medical Oncology
St. James's University Hospital
Leeds, United Kingdom
Speaker's Bureau: Roche, Eisai
Advisory Board: Eisai
Linda Vahdat MD
Professor of Medicine
Director, Breast Cancer Research Program
Head, Solid Tumor Service
Weill Cornell Medical College
New York, New York
Research Support: Eisai
Speaker Honoraria: Eisai, Bristol-Myers Squibb
Amelia Zelnak, MD, MSc
Assistant Professor of Hematology and Oncology
Winship Cancer Institute
Emory University Sc
Research Support: Eisai, Bayer
Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD has nothing to disclose.
Program Manager Sarah Gray, MD has nothing to disclose.
Click here to indicate that you have read this CME information statement and wish to participate in this CME activity.